Radionuclide techniques for brain imaging.
Over the past decade, many of the prime indications for radionuclide brain scanning have become instead indications for CCT, and nuclear medicine studies of the brain have assumed more of a complementary, supportive role. However, there is great promise for improvement in central nervous system radionuclide applications with advances anticipated in both radiopharmaceuticals and instrumentation. Nuclear medicine is continuing to function as a powerful research tool and, in the relatively near future, may regain its role as a major clinical test of the central nervous system.
D001922:Brain Abscess / Q000000981:diagnostic imaging; D001926:Brain Death; D001927:Brain Diseases / Q000000981:diagnostic imaging*; D001930:Brain Injuries / Q000000981:diagnostic imaging; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D002557:Cerebrospinal Fluid Shunts; D002561:Cerebrovascular Disorders / Q000000981:diagnostic imaging; D003937:Diagnosis, Differential; D006801:Humans; D006849:Hydrocephalus / Q000000981:diagnostic imaging; D002538:Intracranial Arteriovenous Malformations / Q000000981:diagnostic imaging; D008581:Meningitis / Q000000981:diagnostic imaging; D015609:Organotechnetium Compounds; D004369:Pentetic Acid; D011877:Radionuclide Imaging; D012851:Sinus Thrombosis, Intracranial / Q000000981:diagnostic imaging; D013118:Spinal Cord Diseases / Q000000981:diagnostic imaging; D013400:Sugar Acids; D013667:Technetium; D016284:Technetium Tc 99m Pentetate
D015609:Organotechnetium Compounds; D013400:Sugar Acids; D013667:Technetium; D004369:Pentetic Acid; C100014:technetium Tc 99m gluceptate; D016284:Technetium Tc 99m Pentetate